{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:26:33Z","timestamp":1783002393375,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,31]]},"DOI":"10.7759\/cureus.53303","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T15:26:31Z","timestamp":1706714791000},"source":"Crossref","is-referenced-by-count":3,"title":["Improved Treatment Outcomes With Modified Induction Therapy in Acute Myeloid Leukemia (AML): A Retrospective Observational Study From a Regional Cancer Center"],"prefix":"10.7759","author":[{"given":"Asif","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amritjot Singh","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Khanikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munlima","family":"Hazarika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha  S","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayanika","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhani","family":"Barbhuiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopam","family":"Deka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13406","article-title":"Acute myeloid leukaemia: challenges and real world data from India","volume":"170","author":"Philip C","year":"2015","unstructured":"Philip C, George B, Ganapule A, et al.. Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol. 2015, 170:110-7. 10.1111\/bjh.13406","journal-title":"Br J Haematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00240","article-title":"Infection prevalence in adolescents and adults with acute myeloid leukemia treated in an Indian tertiary care center","volume":"6","author":"Jain H","year":"2020","unstructured":"Jain H, Rengaraj K, Sharma V, et al.. Infection prevalence in adolescents and adults with acute myeloid leukemia treated in an Indian tertiary care center. JCO Glob Oncol. 2020, 6:1684-95. 10.1200\/GO.20.00240","journal-title":"JCO Glob Oncol"},{"key":"ref4","article-title":"EER Cancer Statistics Review, 1975-2006","author":"Horner MJ","year":"2009","unstructured":"Horner MJ, Ries LAG, Krapcho M, et al.. EER Cancer Statistics Review, 1975-2006. National Cancer Institute, Bethesda, MD; 2009."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett A","year":"2011","unstructured":"Burnett A, Wetzler M, L\u00f6wenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011, 29:487-94. 10.1200\/JCO.2010.30.1820","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner H","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015, 373:1136-52. 10.1056\/NEJMra1406184","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz GJ","year":"2020","unstructured":"Roboz GJ, DiNardo CD, Stein EM, et al.. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020, 135:463-71. 10.1182\/blood.2019002140","journal-title":"Blood"},{"key":"ref8","article-title":"Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B","volume":"58","author":"Rai KR","year":"1981","unstructured":"Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Kaan SK. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981, 58:1203-12.","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20120","article-title":"Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia","volume":"76","author":"Novitzky N","year":"2004","unstructured":"Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia. Am J Hematol. 2004, 76:319-29. 10.1002\/ajh.20120","journal-title":"Am J Hematol"},{"key":"ref10","article-title":"Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study","volume":"69","author":"Preisler H","year":"1987","unstructured":"Preisler H, Davis RB, Kirshner J, Dupre E, Richards F, Hoagland HC, Schulman P. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood. 1987, 69:1441-9.","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb08203.x","article-title":"A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia","volume":"81","author":"Schiller G","year":"1992","unstructured":"Schiller G, Gajewski J, Nimer S, Territo M, Ho W, Lee M, Champlin R. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Br J Haematol. 1992, 81:170-7. 10.1111\/j.1365-2141.1992.tb08203.x","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study","volume":"88","author":"Weick JK","year":"1996","unstructured":"Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Grever M. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996, 88:2841-51.","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809092687","article-title":"Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group","volume":"28","author":"Bishop JF","year":"1998","unstructured":"Bishop JF, Matthews JP, Young GA, Bradstock K, Lowenthal RM. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma. 1998, 28:315-27. 10.3109\/10428199809092687","journal-title":"Leuk Lymphoma"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127623","article-title":"Induction related mortality in acute myeloid leukemia: multivariate model of predictive score from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)","volume":"134","author":"Kayal S","year":"2019","unstructured":"Kayal S, Sengar M, Jain H, Bonda A, George B, Kulkarni UP, Kapoor R. Induction related mortality in acute myeloid leukemia: multivariate model of predictive score from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). Blood. 2019, 134:2615. 10.1182\/blood-2019-127623","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2014152","article-title":"Prevalence of leukemia and associated factors among patients with abnormal hematological parameters in Jimma Medical Center, Southwest Ethiopia: a cross-sectional study","volume":"2020","author":"Kassahun W","year":"2020","unstructured":"Kassahun W, Tesfaye G, Bimerew LG, Fufa D, Adissu W, Yemane T. Prevalence of leukemia and associated factors among patients with abnormal hematological parameters in Jimma Medical Center, Southwest Ethiopia: a cross-sectional study. Adv Hematol. 2020, 2020:1-7. 10.1155\/2020\/2014152","journal-title":"Adv Hematol"},{"key":"ref16","article-title":"Impact of infection prior to the initiation of induction chemotherapy on induction outcomes in patients with newly diagnosed acute leukemia in a tertiary centre hospital in India","author":"Ragesh R","year":"2018","unstructured":"Ragesh R, Seth T, Mahapatra M, Saxena R, Jineesh V. Impact of infection prior to the initiation of induction chemotherapy on induction outcomes in patients with newly diagnosed acute leukemia in a tertiary centre hospital in India. EHA. 2018, PB1730.","journal-title":"EHA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-349258","article-title":"Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study","volume":"118","author":"Thomas X","year":"2011","unstructured":"Thomas X, Elhamri M, Raffoux E, et al.. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood. 2011, 118:1754-62. 10.1182\/blood-2011-04-349258","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-2977","article-title":"Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222","volume":"105","author":"Moore JO","year":"2005","unstructured":"Moore JO, George SL, Dodge RK, et al.. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005, 105:3420-7. 10.1182\/blood-2004-08-2977","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-295279","article-title":"A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study","volume":"117","author":"Miyawaki S","year":"2011","unstructured":"Miyawaki S, Ohtake S, Fujisawa S, et al.. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011, 117:2366-72. 10.1182\/blood-2010-07-295279","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.208637","article-title":"Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia","volume":"105","author":"Talati C","year":"2020","unstructured":"Talati C, Dhulipala VC, Extermann MT, et al.. Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia. Haematologica. 2020, 105:398-406. 10.3324\/haematol.2018.208637","journal-title":"Haematologica"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo CD","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al.. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020, 383:617-29. 10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker FG","year":"2012","unstructured":"R\u00fccker FG, Schlenk RF, Bullinger L, et al.. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012, 119:2114-21. 10.1182\/blood-2011-08-375758","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29940","article-title":"Outcomes of induction therapy in patients with acute myeloid leukemia during the COVID-19 pandemic: a retrospective study from a tertiary cancer center","volume":"14","author":"Iqbal A","year":"2022","unstructured":"Iqbal A, Daniel NR, Reddy R, Hazarika M, Deka R. Outcomes of induction therapy in patients with acute myeloid leukemia during the COVID-19 pandemic: a retrospective study from a tertiary cancer center. Cureus. 2022, 14:e29940. 10.7759\/cureus.29940","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020094","article-title":"The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: a meta-analysis of randomized clinical trials","volume":"99","author":"Wang H","year":"2020","unstructured":"Wang H, Xiao X, Xiao Q, Lu Y, Wu Y. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: a meta-analysis of randomized clinical trials. Medicine (Baltimore). 2020, 99:e20094. 10.1097\/MD.0000000000020094","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/189487-improved-treatment-outcomes-with-modified-induction-therapy-in-acute-myeloid-leukemia-aml-a-retrospective-observational-study-from-a-regional-cancer-center","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:15:57Z","timestamp":1707509757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/189487-improved-treatment-outcomes-with-modified-induction-therapy-in-acute-myeloid-leukemia-aml-a-retrospective-observational-study-from-a-regional-cancer-center"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.53303","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}